R+D

October 1, 2026

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints NewsTrevogrumab cuts semaglutide-induced lean mass loss by…

MMedication

Roche cans muscle-preserving obesity drug, hands it back to Chugai

September 28, 2026

Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with…

HHealthcare

How Lundbeck’s CEO aims to keep firm ‘punching above its weight’

August 22, 2026

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove…

HHealth

ASX healthcare stocks focusing on mitochondrial health

August 12, 2026

Known as the ‘powerhouse of the cell’, mitochondria are becoming a focus of research into ageing, health and…

EEconomy

China overtakes US to lead global R&D spending, hitting $615bn

August 8, 2026

Science Corporate, university expenditures for 2024 include computers, electronics China’s jump in R&D spending was driven by corporate…

EEconomy

China acknowledges ‘temperature gap’ between tech boom and traditional slump

August 3, 2026

A top theoretical journal of the Communist Party has acknowledged that a stark economic divide exists between China’s…

BBusiness

China’s rare earth industry has critical weakness, researchers warn

July 5, 2026

China’s dominance in rare earth mining, refining and exports has long been viewed as a strategic advantage.But a…

AAustralia

Medical technology sector raises fresh concerns with Labor’s capital gains tax overhaul

June 6, 2026

Cutting-edge medical technology companies say new restrictions on tax refunds for research and development will hurt health startups…

AAustralia

lego stars wars IT computer chips repair

April 14, 2026

The ‘Ambitious Australia’ strategic review of Australian R&D from Tesla’s Robyn Denholm is aptly named, but it’s arguably…

EEconomy

Does China’s science budget boost confirm it is listening to everything Elon Musk says?

March 5, 2026

With Beijing allocating 426.42 billion yuan (US$61.7 billion) for the sector, it is positioning frontiers such as future…

MMental health

February 18, 2026

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways stock soars after…

MMedication

February 10, 2026

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRO: Fenebrutinib matched ocrelizumab in slowing PPMS progression,…

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy – Endpoints News

Roche cans muscle-preserving obesity drug, hands it back to Chugai

How Lundbeck’s CEO aims to keep firm ‘punching above its weight’

ASX healthcare stocks focusing on mitochondrial health

China overtakes US to lead global R&D spending, hitting $615bn

China acknowledges ‘temperature gap’ between tech boom and traditional slump

China’s rare earth industry has critical weakness, researchers warn

Medical technology sector raises fresh concerns with Labor’s capital gains tax overhaul

The Denholm R&D report, Ambitious Australia, wants to fix something that isn’t broken

Does China’s science budget boost confirm it is listening to everything Elon Musk says?

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News

Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News